CIK 0001807120 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Design Therapeutics, Inc.
Sign in to watch- Ticker
- DSGN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 823929248
- Phone
- 858-293-4900
- Business address
- 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD, CA, 92011
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-21 | William Arsani Director | Purchase | +25,000 | $18.99 | $475K | 2,797,501 |
| 2022-03-21 | Xu Stella Director | Sale | −24,000 | $19.01 | $456K | 4,131,405 |
| 2022-03-18 | Xu Stella Director | Sale | −552,225 | $19.04 | $10.5M | 4,168,605 |
| 2022-03-18 | Xu Stella Director | Sale | −13,200 | $20.34 | $268K | 4,155,405 |
| 2022-03-16 | Prasad Deepa Director | Other acquisition | +11,806 | 11,806 | ||
| 2022-02-01 | Jeffries Sean Chief Operating Officer | Grant or award · Stock Option (right to buy) | +350,000 | 350,000 | ||
| 2022-02-01 | Shah Pratik Executive Chairperson | Grant or award · Stock Option (right to buy) | +475,000 | 475,000 | ||
| 2022-02-01 | Siffert Joao MD President and CEO | Grant or award · Stock Option (right to buy) | +475,000 | 475,000 | ||
| 2022-02-01 | Burgess Julie Chief Accounting Officer | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2021-10-01 | Burgess Julie Chief Accounting Officer | Grant or award · Stock Option (right to buy) | +135,000 | 135,000 | ||
| 2021-08-31 | William Arsani Director | Purchase | +40,000 | $15.45 | $618K | 2,772,501 |
| 2021-06-15 | Prasad Deepa Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2021-06-15 | Behanna Heather Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2021-03-30 | William Arsani Director | Conversion | +1,217,627 | 1,217,627 | ||
| 2021-03-30 | William Arsani Director | Conversion | +814,874 | 814,874 | ||
| 2021-03-30 | William Arsani Director | Purchase | +700,000 | $20.00 | $14.0M | 700,000 |
| 2021-03-30 | Cormorant Asset Management, LP Former 10% Owner | Conversion | +4,364,844 | 4,364,844 | ||
| 2021-03-30 | Cormorant Asset Management, LP Former 10% Owner | Purchase | +750,000 | $20.00 | $15.0M | 5,114,844 |
| 2021-03-30 | Cormorant Asset Management, LP Former 10% Owner | Conversion · Series A Convertible Preferred Stock | −2,959,891 | 0 | ||
| 2021-03-30 | Cormorant Asset Management, LP Former 10% Owner | Conversion · Series B Convertible Preferred Stock | −1,404,953 | 0 |
Page 5 of 7 · 135 trades